Bevacizumab biosimilar is under clinical development by Gedeon Richter and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Bevacizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bevacizumab biosimilar overview

Bevacizumab biosimilar is under development for the treatment of  metastatic colorectal cancer, non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma and metastatic renal cell carcinoma. The drug candidate is administered through intravenous route. It is a recombinant humanized monoclonal antibody that targets the human vascular endothelial growth factor A (VEGF-A). It is developed using selexis sure technology. The technology is based on DNA elements that control the dynamic organization of chromatin within cells and allow for higher and stable expression of recombinant proteins.

Gedeon Richter overview

Gedeon Richter is a pharmaceutical company that develops, manufactures and markets a wide range of drugs including original, generic, and licensed products and over the counter (OTC) medicines. The company’s product portfolio consists of medicines to treat gynecological diseases, cardiovascular diseases, gastrointestinal diseases, and central nervous system disorders. Richter’s research activities focus exclusively on the development of original small molecules, recombinant biotechnology, and generic product development. It operates sales network in Hungary, Central Eastern Europe, and the Commonwealth of Independent States (CIS) countries. The company has a research and development unit in Central Eastern Europe. Gedeon Richter is headquartered in Budapest, Hungary.

For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.